Jiawei Xianglian Decoction (JWXLD), a Traditional Chinese Medicine (TCM), Alleviates CPT-11-Induced Diarrhea in Mice

Irinotecan (CPT-11) is used for therapy of various cancers. However, it has several serious adverse reactions such as diarrhea which is caused by SN-38, the active form of CPT-11. This study aimed to evaluate the effectiveness of Jiawei xianglian decoction (JWXLD), which has been widely used for the treatment of diarrhea in China. In this study, a mouse model with delayed diarrhea was generated by CPT-11. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were performed to explore intestinal microflora and inflammatory cytokine. Hematoxylin and eosin (H&E) staining was used to analyze tissue morphology. We found that 0.12, 0.23, and 0.46 g JWXLD significantly reduced the severity of CPT-11-induced diarrhea. The levels of Lactobacillus (Lacto) and Bifidobacterium (Bifid) were significantly downregulated by CPT-11, and these effects can be reversed by JWXLD treatment. Furthermore, JWXLD was observed to decrease the activity of β-glucuronidase (β-GD). Histopathological data showed that CPT-11 induced severe intestinal mucosal injury, which was characterized as grade 6, and JWXLD significantly alleviated the injury. In addition, CPT-11 increased the productions of tumor necrosis factor-alpha (TNF-α), tumor necrosis factor-beta (TNF-β), interleukin-6 (IL-6), and interleukin-1 (IL-1), but decreased interleukin-15 (IL-15), interleukin-7 (IL-7), and uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1). In conclusion, JWXLD can counteract these effects caused by CPT-11 treatment. JWXLD could alleviate CPT-11-induced diarrhea.

[1]  J. Zhang,et al.  Preventative effects of selenium-enriched Bifidobacterium longum on irinotecan-induced small intestinal mucositis in mice. , 2019, Beneficial microbes.

[2]  Jung-Hye Choi,et al.  Effect of Dehydrocostus Lactone Isolated from the Roots of Aucklandia lappa on the Apoptosis of Endometriotic Cells and the Alternative Activation of Endometriosis-Associated Macrophages. , 2019, The American journal of Chinese medicine.

[3]  Yihan Wu,et al.  Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Irinotecan , 2018, Reactions Weekly.

[5]  J. Li,et al.  Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. , 2018, Cancer research.

[6]  N. Ikarashi,et al.  CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon , 2018, International journal of molecular sciences.

[7]  Xiaomei Luo,et al.  Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity , 2017, Front. Pharmacol..

[8]  M. Shimada,et al.  TU-100 exerts a protective effect against bacterial translocation by maintaining the tight junction , 2017, Surgery Today.

[9]  Min Huang,et al.  Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation , 2017, Cell Research.

[10]  Yuichi Sugiyama,et al.  Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects , 2017, Pharmaceutical Research.

[11]  Yingying Chen,et al.  Gegen Qinlian decoction alleviates experimental colitis via suppressing TLR4/NF-κB signaling and enhancing antioxidant effect. , 2016, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[12]  Dong-Wan Kim,et al.  Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[13]  N. Zhou,et al.  UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer , 2016, Cancer Chemotherapy and Pharmacology.

[14]  Naoki Tanaka,et al.  Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression. , 2016, Toxicology and applied pharmacology.

[15]  Q. Mei,et al.  The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer , 2015, OncoTargets and therapy.

[16]  Qiang Xu,et al.  CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings. , 2015, Toxicology and applied pharmacology.

[17]  M. Teixeira,et al.  Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. , 2015, Microbiology.

[18]  Hongyi Zhang,et al.  Subzero-Temperature Liquid-Liquid Extraction Coupled with UPLC-MS-MS for the Simultaneous Determination of 12 Bioactive Components in Traditional Chinese Medicine Gegen-Qinlian Decoction. , 2015, Journal of chromatographic science.

[19]  K. Rahman,et al.  Portulaca oleracea L.: A Review of Phytochemistry and Pharmacological Effects , 2015, BioMed research international.

[20]  Edward Chu,et al.  The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018) , 2014, BMC Complementary and Alternative Medicine.

[21]  Y. H. Kim,et al.  Anti-inflammatory components of Euphorbia humifusa Willd. , 2014, Bioorganic & medicinal chemistry letters.

[22]  S. Mani,et al.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. , 2013, Current drug targets.

[23]  Kazuyuki Inoue,et al.  Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. , 2013, The Tohoku journal of experimental medicine.

[24]  P. Houghton,et al.  Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors , 2012, Pediatric blood & cancer.

[25]  Matthew R. Redinbo,et al.  Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.

[26]  孙霄茜,et al.  Evidence-based Complementary and Alternative Medicine简介 , 2009 .

[27]  A. Stringer,et al.  Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats , 2008, Cancer biology & therapy.

[28]  Gallegos-Castorena Sergio,et al.  Activated charcoal to prevent irinotecan‐induced diarrhea in children , 2008, Pediatric blood & cancer.

[29]  S. Sonis,et al.  Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis , 2008, Cancer Chemotherapy and Pharmacology.

[30]  F. Cunha,et al.  Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide , 2008, Cancer Chemotherapy and Pharmacology.

[31]  W. Fischbach,et al.  Phase II Clinical Trial for Prevention of Delayed Diarrhea with Cholestyramine/Levofloxacin in the Second-Line Treatment with Irinotecan Biweekly in Patients with Metastatic Colorectal Carcinoma , 2007, Oncology.

[32]  J. Verweij,et al.  Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. , 2006, The oncologist.

[33]  G. Brandi,et al.  Intestinal microflora and digestive toxicity of irinotecan in mice. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  M. Blaut,et al.  Modulation of gut mucosal biofilms , 2005, British Journal of Nutrition.

[35]  H. Holzhausen,et al.  Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats , 2004, Journal of Cancer Research and Clinical Oncology.

[36]  M. R. Inglis,et al.  Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer , 2003, Journal of gastroenterology and hepatology.

[37]  J Verweij,et al.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  O. Sreekumar,et al.  Immediate effect of Lactobacillus acidophilus on the intestinal flora and fecal enzymes of rats and the in vitro inhibition of Escherichia coli in coculture. , 2000, Journal of dairy science.

[39]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[40]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.

[41]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[42]  H. Scott,et al.  Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. , 1970, Archives of surgery.

[43]  C. Tzeng,et al.  Pharmacological inhibition of bacterial &bgr;‐glucuronidase prevents irinotecan‐induced diarrhea without impairing its antitumor efficacy in vivo , 2019, Pharmacological research.

[44]  I. Kato,et al.  Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen , 2010, Cancer Chemotherapy and Pharmacology.

[45]  S. Marsh,et al.  Irinotecan pharmacogenomics. , 2010, Pharmacogenomics.

[46]  E. Cvitkovic,et al.  Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. , 1996, European journal of cancer.